ConvergeHEALTH by Deloitte Announces Health System Intellect, a Comprehensive Analytics Solution Suite to Manage Margin, Cost and Quality
Provides industry leading insights leveraging clinical, financial and operational data
Today at HIMSS14, ConvergeHEALTH by Deloitte announces the availability of Health System Intellect, an industry leading analytics solution that provides integrated views of clinical, operational and financial analytics to optimize reporting and performance at the process and key performance indicator level.
Health System Intellect will help health systems:
- Leverage comparative analytics with a health system's existing information systems
- Translate data into actionable insight
- Benefit from Deloitte's decades of experience helping health systems address cost, revenue and quality improvements
ConvergeHEALTH's Health System Intellect suite, combined with Deloitte's practices in clinical information systems, revenue cycle, clinical effectiveness, decision support and performance improvement, will allow health systems to lower cost of services, increase patient satisfaction, align revenue with value, reduce unnecessary utilization and process variation, enable continuous improvement programs, and improve knowledge sharing across functions.
"Health systems are facing tremendous challenges to reduce costs, improve quality and work within new reimbursement models," said Asif Dhar, principal, Deloitte Consulting LLP, chief medical informatics officer and executive vice president of solutions for ConvergeHEALTH. "Our analytics will enable organizations to have a more complete view of performance so that decisions about cost are not made at the expense of quality, nor do they sub-optimize performance in other areas of the health system.
"The analytics will help clients get to the root cause of performance issues, pinpointing manageable clinical, operational and financial process variance so that organizations can improve quality while decreasing cost and maximizing revenue," Dhar continued. "Combined with Deloitte's proven approaches to managing cost, quality and revenue, our analytics solutions focus teams on measures, actions and real team-oriented solutions."
"Deloitte's consulting practices have been guiding health care organizations to improve their clinical and operational performance for many years, and now clients can benefit by having an enterprise analytics environment to drive continuous improvement through the Intellect integrated platform for organizational transformation," said Doug Beaudoin, principal, Deloitte Consulting LLP and a leader of Deloitte's life sciences and health care practice. "We are proud to continue to help health systems use data to transform their clinical and operational enterprises for the ultimate benefit of patients."
ConvergeHEALTH is showcasing its solutions in Orlando, Fla., Feb. 23-26 at the HIMSS14 conference in Booth 1611.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
